09.03.19

Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at EURETINA

Source: Allegro Ophthalmics

Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate nonexudative age-related macular degeneration (dry AMD) will be presented during the European Society of Retina Specialists (EURETINA) Congress that is being held September 5-8 in Paris, and at The Retina Society 2019 Annual Meeting, which is being held September 11-15 in London.

In June, Allegro announced topline results of the risuteganib phase 2 intermediate dry AMD clinical trial, which met its primary endpoint with 48 percent of patients in the risuteganib arm at week 28 gaining ≥ 8 letters in visual acuity from baseline, compared to 7 percent of patients in the sham group at week 12 (P=0.013). Risuteganib was found to be safe with no reported drug related serious adverse events (SAEs). In addition to complete best corrected visual acuity (BCVA) data, secondary outcomes for several patient cases will be presented at EURETINA and The Retina Society meeting.

Allegro also announced that the results of its ALG-1007 ex-U.S. proof-of-concept clinical trial for the treatment of dry eye disease (DED) will be presented during the European Society of Cataract and Refractive Surgeons (ESCRS), which is being held September 14-18 in Paris. ALG-1007, a topical drop, is the company’s second exploratory integrin-regulating drug candidate. In May, Allegro announced that the ex-U.S. proof-of-concept clinical trial concluded that ALG- 1007 was well-tolerated and demonstrated a dose-response with improvement of the signs and symptoms of DED as early as 2 weeks.

“Allegro is excited to present for the very first time the results of our risuteganib phase 2 intermediate dry AMD trial as well as those of our ALG-1007 ex-US proof-of-concept DED study to the European ophthalmic community,” Vicken Karageozian, MD, president and CEO, Allegro Ophthalmics, said in a company news release. “It is encouraging to see such visual acuity gains in patients with dry AMD, a sight-threatening disease for which there is currently no available treatment. In addition, the early positive results of the ALG-1007 proof-of-concept study for dry eye disease, which impacts millions of people across the globe, appear promising.”

The scientific presentations are scheduled as follows:

Sunday, September 8: 9:30-9:36 AM
EURETINA, Palais des Congrès, Paris, France (Amphithéâtre Havane)
Safety and Efficacy of Risuteganib in Non Exudative Age-Related Macular Degeneration: Primary Results from a Phase 2 Study
Peter K. Kaiser, MD

Thursday, September 12: 2:44-2:50 PM
The Retina Society 2019 Annual Meeting, The Landmark London, London, UK (Grand Ballroom)
Safety and Efficacy of Risuteganib in Intermediate Non-exudative (Dry) Age-Related Macular Degeneration (AMD): Primary Results from a Phase 2 Study
David S. Boyer, MD

Monday, September 16: 9:48-9:54 AM
ESCRS, Paris Expo, Porte de Versailles, Paris, France (Free Paper Forum: Podium 2)
Safety and Efficacy of a Novel Integrin Inhibitor ALG-1007 Topical Ophthalmic Solution for the Treatment of Dry Eye Disease
Eric Donnenfeld, MD

Related Content